[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337174-105":59,"doc-detail-337174-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","exosome-delivered-nr2f1-as1-and-nr2f1-drive-phenotypic-transition-from-dormancy-to-proliferation-in-treatment-resistant-prostate-cancer-via-stabilizing-hormonal-receptors","Exosome-delivered NR2F1-AS1 and NR2F1 - drive phenotypic transition from dormancy to proliferation in treatment-resistant prostate cancer via stabilizing hormonal receptors","","Cancer cells can reprogram phenotype under targeted therapies, but how drug-resistant prostate cancer cells shift from dormancy to active proliferation remains unclear. This study uses high-plasticity mouse models and enzalutamide-resistant (ENZ-R) systems to define NR2F1 as a key lineage-transition factor. NR2F1 depletion promotes a dormancy-like ENZ-R state with reduced proliferation and stronger drug resistance, while NR2F1 overexpression reverses these effects. Exosome-driven NR2F1-AS1 and NR2F1 regulate hormonal receptor signaling to reawaken dormant cells.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exosome-delivered-nr2f1-as1-and-nr2f1-drive-phenotypic-transition-from-dormancy-to-proliferation-in-treatment-resistant-prostate-cancer-via-stabilizing-hormonal-receptors/337174/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exosome-delivered-nr2f1-as1-and-nr2f1-drive-phenotypic-transition-from-dormancy-to-proliferation-in-treatment-resistant-prostate-cancer-via-stabilizing-hormonal-receptors/337174.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the study address regarding ENZ-resistant prostate cancer?","Question",{"text":113,"@type":114},"It investigates the poorly understood transition from dormancy to proliferation in drug-resistant prostate cancer cells during enzalutamide (ENZ) treatment.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does NR2F1 affect dormancy and proliferation in ENZ-R models?",{"text":118,"@type":114},"NR2F1 depletion drives ENZ-R cells toward a dormancy-like state with reduced proliferation and heightened drug resistance, whereas NR2F1 overexpression produces opposite effects.",{"name":120,"@type":111,"acceptedAnswer":121},"What role do exosomes and NR2F1-AS1 play in the observed phenotypic transition?",{"text":122,"@type":114},"Transcriptional analyses indicate exosomes are enriched, and NR2F1-AS1 forms a complex with SRSF1 to increase NR2F1 expression; exosomal NR2F1 and NR2F1-AS1 then promote proliferation of dormant ENZ-R cells.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},337174,1790868384,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Chen et al. Journal of Nanobiotechnology (2024) 22:761  \n[https://doi.org/10.1186/s12951-024-03025-y](https://doi.org/10.1186/s12951-024-03025-y)  \nJournal of Nanobiotechnology  \nRESEARCH Open Access  \nExosome-delivered NR2F1-AS1 and NR2F1   drive phenotypic transition from dormancy to proliferation in treatment-resistant prostate cancer via stabilizing hormonal receptors  \nWenbin Chen 1*†, Yiyou Mao2†, YiYuan Zhan2†, Wenfeng Li 1, Jun Wu2, Xiangming Mao2*, Bin Xu 1* and Fangpeng Shu3*  \nAbstract  \nCancer cells acquire the ability to reprogram their phenotype in response to targeted therapies, yet the transition from dormancy to proliferation in drug-resistant cancers remains poorly understood. In prostate cancer, we utilized high-plasticity mouse models and enzal utamide-resistant (ENZ-R) cellular models to elucidate NR2F1 as a key factor in lineage transition and ENZ resistance. Depletion of NR2F1 drives ENZ-R cells into a relative dormancy state, characterized by reduced proliferation and heightened drug resistance, while NR2F1 overexpression yields contrasting outcomes. Transcriptional sequencing analysis of NR2F1-silenced prostate cancer cells and tissues from the Cancer Genome Atlas-prostate cancer and SU2C cohorts indicated exosomes as the most enriched  \ncell component, with pathways implicated in steroid hormone biosynthesis and drug metabolism. Moreover, NR2F1-AS1 forms a complex with SRSF1 to upregulate NR2F1 expression, facilitating its binding with ESR1 to sustain hormonal receptor expression and enhance proliferation in ENZ-R cells. Furthermore, HnRNPA2B1 interacts with NR2F1 and NR2F1-AS1, assisting their packaging into exosomes, wherein exosomal NR2F1 and NR2F1-AS1 promote the proliferation of dormant ENZ-R cells. Our works offer novel insights into the reawaking of dormant drug-resistant cancer cells governed by NR2F1 upregulation triggered by exosome-derived NR2F1-AS1 and NR2F1, suggesting therapeutic potential for phenotype reversal.  \n†Wenbin Chen, Yiyou Mao andYiYuan Zhan contributed equally to this work.  \n*Correspondence: Wenbin Chen [edwincham13@qq.com](edwincham13@qq.com)[ ](edwincham13@qq.com)Xiangming Mao [mxm@smu.edu.cn](mxm@smu.edu.cn)[ ](mxm@smu.edu.cn)Bin Xu [chxb2004@shsmu.edu.cn](chxb2004@shsmu.edu.cn)[ ](chxb2004@shsmu.edu.cn)Fangpeng Shu [15625060053@163.com](15625060053@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nChen et al. Journal of Nanobiotechnology (2024) 22:761 Page 2 of 18  \nGraphical Abstract  \nKeywords Prostate cancer, NR2F1, Exosomes, Phenotypic transition, Treatment-resistant  \nIntroduction  \nResistance to targeted therapies has transformed the canonical trajectories of tumors, especially regarding the utilization of androgen receptor pathway inhibitors (ARPIs) in prostate cancer (PCa) treatment [1, 2]. Enzalutamide (ENZ), among the most effective ARPIs, is recommended for the tr","cbCaii4IA7xhCzxY","https://ap.wps.com/l/cbCaii4IA7xhCzxY","pdf",16077807,18,"English","# Abstract\n## Introduction\n## Materials and methods","[{\"question\":\"What problem does the study address regarding ENZ-resistant prostate cancer?\",\"answer\":\"It investigates the poorly understood transition from dormancy to proliferation in drug-resistant prostate cancer cells during enzalutamide (ENZ) treatment.\"},{\"question\":\"How does NR2F1 affect dormancy and proliferation in ENZ-R models?\",\"answer\":\"NR2F1 depletion drives ENZ-R cells toward a dormancy-like state with reduced proliferation and heightened drug resistance, whereas NR2F1 overexpression produces opposite effects.\"},{\"question\":\"What role do exosomes and NR2F1-AS1 play in the observed phenotypic transition?\",\"answer\":\"Transcriptional analyses indicate exosomes are enriched, and NR2F1-AS1 forms a complex with SRSF1 to increase NR2F1 expression; exosomal NR2F1 and NR2F1-AS1 then promote proliferation of dormant ENZ-R cells.\"}]","Exosome-delivered NR2F1-AS1 and NR2F1 - drive phenotypic transition from dormancy to proliferation in treatment-resistant prostate cancer via stabilizing hormonal receptors | PDF",1790018010,45,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cfc854a6e0a7ab1468727ec4fd32cb4e.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/689dd6936e5c38b3f77f26d1ef6eabf3.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/340a1fd3640cf9d9372f8a4fddebae3c.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/13c74e725b4bcf97d0a4d82a3208c3bf.webp",980,1306]